Floatz logo

Sandostatin

Advanced Cancer

Grupo Espanol de Tumores NeuroendocrinosPhase 2/3Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
73/ 100

Competitive context

1412 Active assets in the Advanced Cancer cohort.

View all 50

Same molecule, other indications

Sandostatin is also rated in:

diarrheal diseaseDormant
B
Indicative ·
62 / 100
View asset →
HyperphagiaDormant
B
Indicative ·
57 / 100
View asset →
Prader-Willi syndromeDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →